Blueprint Medicines Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	26.58	19.63	18.03	17.16	13.98
Revenue Growth (YoY)	47.92%	8.86%	5.11%	22.75%	-
Cost of Revenue	31.6	31.96	44.17	28.41	18.35
Gross Profit	-5.02	-12.33	-26.14	-11.26	-4.37
Selling, General & Admin	136.87	135.01	145.49	82.24	54.78
Research & Development	267.57	266.16	239.61	142.55	136.82
Operating Expenses	404.45	401.17	385.11	224.85	191.59
Operating Income	-409.47	-413.5	-411.25	-236.11	-195.96
Interest Expense	-3.15	-2.26	-2.56	-1.36	-1.52
Interest & Investment Income	14.74	15.37	7.63	2.27	0.24
Earnings From Equity Investments	0.22	0.11	0.11	-0	0.01
Currency Exchange Gain (Loss)	0.49	0.1	0.09	1.52	-0.51
Other Non Operating Income (Expenses)	5.79	5.82	4.86	2.41	8.97
EBT Excluding Unusual Items	-391.38	-394.36	-401.11	-231.27	-188.76
Gain (Loss) on Sale of Investments	5.07	-0.62	-	-	-
Gain (Loss) on Sale of Assets	-	-0.14	-0.13	-	-0.2
Pretax Income	-386.31	-395.12	-401.24	-231.27	-188.96
Income Tax Expense	-	-	0	-	-
Earnings From Continuing Operations	-386.31	-395.12	-401.24	-231.27	-188.96
Minority Interest in Earnings	6.42	5.7	2.48	1.14	-
Net Income	-379.89	-389.42	-398.76	-230.13	-188.96
Net Income to Common	-379.89	-389.42	-398.76	-230.13	-188.96
Shares Outstanding (Basic)	58	57	46	39	33
Shares Outstanding (Diluted)	58	57	46	39	33
Shares Change (YoY)	18.48%	23.33%	17.94%	17.87%	-
EPS (Basic)	-6.56	-6.83	-8.62	-5.87	-5.68
EPS (Diluted)	-6.56	-6.83	-8.62	-5.87	-5.68
Free Cash Flow	-577.93	-523.91	-196.48	-167.48	-122.32
Free Cash Flow Per Share	-9.98	-9.18	-4.25	-4.27	-3.68
Gross Margin	-18.90%	-62.79%	-144.96%	-65.61%	-31.27%
Operating Margin	-1540.75%	-2106.35%	-2280.52%	-1376.17%	-1402.03%
Profit Margin	-1429.44%	-1983.67%	-2211.26%	-1341.32%	-1351.93%
Free Cash Flow Margin	-2174.61%	-2668.77%	-1089.53%	-976.14%	-875.12%
EBITDA	-390.25	-394.04	-392.04	-217.36	-178.32
D&A For EBITDA	19.22	19.46	19.21	18.75	17.65
EBIT	-409.47	-413.5	-411.25	-236.11	-195.96

Source: S&P Global Market Intelligence. Standard template. Financial Sources.